TIRZEPATIDE REDUCES ALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES: POST HOC POOLED ANALYSIS OF SURPASS-1 to -5
Canadian journal of diabetes(2023)
Abstract
A post hoc analysis of the SURPASS-4 trial suggested that the glucose-dependent insulinotropic polypeptide/ glucagon-like peptide-1 (GIP/GLP-1) receptor agonist tirzepatide (TZP) could have a potential kidney protective effect in people with T2D and high cardiovascular risk by slowing the rate of estimated glomerular filtration rate (eGFR) decline and reducing urine albumin-creatinine ratio (UACR) vs insulin glargine over 2 years. In the current post hoc analysis, we explored effects of TZP on UACR changes in SURPASS-1 to -5 trials.
MoreTranslated text
Key words
Type 2 Diabetes
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined